[PDF] Top 20 La cuestión catalana en la Segunda República

... packed adipocytes were incubated in serum-free DMEM (5.5 or 25 mM glucose) for 24 ...once. Adipocytes were then ultracentrifuged in 10 mM Tris-HCl buffer (pH ...at 4 ° C, and 400 µ L of the ... See full document

... with dipeptidyl peptidase-4 (DPP-4) inhibitors, novel oral antidiabetic agents (OADs), results in improvements in the blood glucose levels in patients with type 2 diabetes mellitus ... See full document

... [7]. Dipeptidyl peptidase 4 (DPP-4) inhibitors have become a useful class of oral hypoglycemic agents (OHA) for the treatment of T2DM since ...immune regulation, cell apoptosis, and ... See full document

... hepatic glucose production, followed by the addition of a sulfonylurea, a class of antihyperglycemic agent which mediates glucose- independent insulin secretion ...a dipeptidyl ... See full document

... multiple metabolic abnormalities underlying type 2 diabetes, combination therapies may result in improved adherence due to the smaller number of pills needed to be taken daily, and in some cases a reduction in overall ... See full document

... In contrast, sulfonylureas (insulin secretagogues) may not be considered as initial therapy, but rather for use at a lower dose to support the insulinotropic effect of incretin therapy, because of their risk of ... See full document

... Alogliptin is a new addition to incretin based therapies for type 2 diabetes. Like other agents in the DPP-4 inhibitor class, it offers good tolerability, lack of severe hypoglycemia, and weight neutrality as ... See full document

... Abstract: Type 2 diabetes mellitus is a progressive disease associated with significant morbidity and mortality. There is good evidence showing that intensive glycemic control reduces the development and progression of ... See full document

... production of the members of cathepsin and matrix metalloproteinase (MMP) families from cultured vascular cells (i.e., vascular smooth muscles and endothelial cells), monocyte-derived macrophages, mast cells and, ... See full document

... blood glucose levels and has beneficial effects on beta cell proliferation and function, including insulin biosynthesis and secretion, in a glucose dependent manner 1 ...of glucose levels 2 - 7 ... See full document

... domized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of adding sitagliptin 100 mg versus placebo to T2DM patients established on pioglita- zone 30–45 mg/day. In the 8 to 14-week pretrial ... See full document

... for 4 weeks revealed a median time to maximum concentration (Cmax) of ...blood glucose, and 2-hour postprandial blood glucose levels in patients with type 2 ... See full document

... Initial proof-of-principle studies were performed using pharmacological doses of GLP-1 administered by intra- venous or subcutaneous infusion. As well as stimulating insulin [29] and inhibiting glucagon secretion, both ... See full document

... Several studies have also reported the benefits of gly- caemic control with DPP4i-based therapy in combination with insulin. Chen et al. [16] conducted a meta-analysis of seven randomized controlled trials of combination ... See full document

... of dipeptidyl peptidase-4 inhibitors (DPP-4i): sitagliptin and vildagliptin on augmentation index standardized for 75 beats per minute (cAiX@75), blood pressure (BP), lipid profile and ... See full document

... the glucose-lowering potency of the medication; the presence of co- morbid conditions in the patient being treated; possible adverse side effects of the drugs being used; the risk of hypoglycemia with given ... See full document

... the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double- blind, ... See full document

... MAIN MESSAGE Two classes of incretin agents are currently available: glucagonlike peptide 1 (GLP1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, both of which lower hyperglycemia ... See full document

... Diabetes is also a strong risk factor for CV events. Insulin resistance (IR) frequently leads to high very low-density lipoprotein (VLDL) and low HDL concen- trations; therefore, residual risks are often critical in pa- ... See full document

... adipose-specific protein which is negatively correlated with proatherogenic LDL-C and other cardiovascular risk factors for diabetes or IR [42]. In the current sub- group analysis, DPP-4i improved CRP concentrations in ... See full document